Ciro roberto Rinaldi - University of Lincoln

基本信息

浏览量：38

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 48 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Lindsay A. M. Rein,Firas El Chaer,Junichiro Yuda,Kazuya Shimoda,Raajit Rampal,Joseph M. Scandura,Akiyoshi Takami,James Mccloskey,Michiko Ichii,Shuichi Shirane,Alessandra Iurlo,Prithviraj Bose,Alessandro Lucchesi,Giulia Benevolo,Idoroenyi Amanam,Pankit Vachhani,Srinivas K. Tantravahi, Marcello Rotta,Yasushi Onishi,Jean-Jacques Kiladjian,Ciro Rinaldi,Nikki Granacher,Terrence Bradley,Anand Ashwin Patel,Michael Loschi,Samah Alimam, Stanley Cheung,Vincent Ribrag,Sujan Kabir, Masataka Seki,Karen Ansaldo Pharmd, Guia Guffanti, Jinny Lee, Steven L. Warner,Jason M. Foulks,Ruben Mesa

BLOOD (2024): 3180-3181

引用0浏览0引用

Phase 2 Study of the Lysine-Specific Demethylase 1 (LSD1) Inhibitor Bomedemstat in Patients with Polycythemia Vera (PV)

Ciro Rinaldi,Lindsay Rein, Alice Livings,Andrew J. Innes,Kristen Pettit, Paul Yeh,Stephen R. Larsen,Anne-Marie Watson,Michael F. Leahy,Natalia Curto-Garcia, Ali Mahdi,Rebecca Frewin, Haifz Qureshi, Joseph Shatzel, Jennifer Vaughn,Tsewang Tashi,Harshad Amin, Uzor Ogbu, Burak Gumuscu,David M. Ross

Journal of Clinical Oncologyno. 16_suppl (2024): TPS6595-TPS6595

引用0浏览0引用

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Firas El Chaer,Lindsay A.M. Rein,Junichiro Yuda,Kazuya Shimoda,Akiyoshi Takami,Michiko Ichii,James McCloskey,Joseph M. Scandura,Alessandra Iurlo,Prithviraj Bose,Tamanna Haque,Alessandro Lucchesi,Shuichi Shirane,Giulia Benevolo,Idoroenyi Amanam,Jean-Jacques Kiladjian,Pankit Vachhani,Srinivas K Tantravahi,Yasushi Onishi,Ciro Rinaldi, Marcello Rotta,Nikki Granacher,Anand Ashwin Patel,Michael Loschi,Samah Alimam,Terrence Bradley, Stanley Cheung,Vincent Ribrag,Sujan Kabir,Karen Ansaldo, Masataka Seki, Vincent Loksa, Zhonggai Li,Jason M. Foulks, Jatin Shah,Raajit Rampal

Bloodno. Supplement 1 (2024): 655-655

引用0浏览0引用

Supplementary Figure 5 from Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis

Vitalyi Senyuk,Kislay K. Sinha,Donglan Li,Ciro R. Rinaldi,Sastry Yanamandra,Giuseppina Nucifora

crossref（2023）

引用0浏览0引用

Supplementary Figure 2 from Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis

Vitalyi Senyuk,Kislay K. Sinha,Donglan Li,Ciro R. Rinaldi,Sastry Yanamandra,Giuseppina Nucifora

crossref（2023）

引用0浏览0引用

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY

Ciro Rinaldi,Kristian Boasman,Matthew Simmonds

HemaSphereno. S3 (2023)

引用0浏览0引用

Supplementary Figure 3 from Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis

Vitalyi Senyuk,Kislay K. Sinha,Donglan Li,Ciro R. Rinaldi,Sastry Yanamandra,Giuseppina Nucifora

crossref（2023）

引用0浏览0引用

Ruxolitinib and Magrolimab significantly increases Calreticulin expression in Myelofibrosis. Proof of concept for combination therapy

Kristian Boasman,Matthew J. Simmonds,Ciro Rinaldi

BRITISH JOURNAL OF HAEMATOLOGY（2023）

引用0浏览0引用

Combination of Ruxolitinib and Magrolimab Significantly Increases Calreticulin Expression in Myelofibrosis CD34+ Cells in Vitro. Proof of Concept for Combination Therapy

Kristian Boasman,Matthew J. Simmonds,Ciro R. Rinaldi

Blood（2022）

引用2浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn